|
|
| |
| Your words hold up. The juggling is what slips. |
| Words are not the part that goes. A team from two Boston labs put that to the test. They scanned younger adults, aged 17 to 39. They scanned older adults, aged 41 to 80. Everyone listened to stories and read sentences in the scanner. Then everyone did hard puzzles with no words in them at all. |
| Let me explain what they were watching. Your brain keeps a dedicated language network. It does one job. It has done that one job for sixty years. Your brain also keeps an all-purpose network. That one steps in for anything hard and new. |
| One network did not budge. The language network looked the same in both groups. Same map. Same strength. Same wiring. The all-purpose network did not hold. In the older adults it was smaller, weaker and less in step with itself. |
| |
Picture two roads out of your town. One you drive every single day, and it stays clear. The back lanes grow over. |
|
| One study, one moment in time. I could be wrong about the cause. Maybe a circuit built for one job is simply tougher. Maybe daily use keeps it paved. But the split matches what most men actually feel. The words are still there. The switching feels slow. |
| So stop fearing the lost word. I urge you to watch the juggling instead. Two things at once, plans that change, a new gadget. That is the part worth guarding. |
| Billot, Jhingan, Kiran & Fedorenko · MIT & Boston University · Nature Communications · Aug 24 2026 |
|
|
|
|
| |
| Book the flu shot this week |
| September is the quiet window. The season has not turned yet. Your body needs about two weeks to build its cover. So the shot you book now is ready when the flu arrives. |
| Two reasons put this in a brain newsletter. The first is plain and hard. A bad flu at seventy often means a hospital bed. Older men come out of those beds confused for days. And a confused stretch in hospital can leave a dent in thinking that never fully lifts. |
| The second reason is softer. Researchers at UTHealth Houston matched 935,887 older Americans into pairs. One of each pair had a flu shot. One did not. Over four years, the vaccinated side had about 40% lower odds of an Alzheimer’s diagnosis. |
| Hold that number loosely. It came from insurance records, not a trial. Men who get their shots also see their doctors more. The hospital argument stands on its own anyway. |
| The Protocol |
| When |
| Within the next two weeks, while the pharmacy is quiet |
| Duration |
| One shot. Once a year. Ten minutes of your day. |
| Rules |
| Past 65? Ask for the stronger version made for older adults. Other shots can often go in the same visit — ask. A sore arm for a day is normal. Running a fever today? Wait until it passes. |
| |
| You are watching for nothing at all. A winter you barely notice, and no hospital bed. No shot is proven to stop dementia. I urge you to put it in the calendar today. |
|
|
|
|
|
|
|
| Twenty minutes on a bike rescued their memory |
| Lost sleep hits memory first. A team at McGill kept 54 adults awake for 30 hours. Then some rode a bike for twenty minutes. Some napped for ninety. The rest did nothing. Three days later, the riders and the nappers both scored about 22% better on a picture test. Two very different routes, one result. These were young adults, not men of sixty. And nothing here replaces a night of sleep. |
| McGill University · Proceedings of the National Academy of Sciences · Aug 24 2026 |
|
|
| Your temperament is partly written in |
| There is no personality gene. A team led from Michigan State pooled 46 groups of volunteers. They matched stored gene samples against the five standard traits. More than 1,200 gene variants turned up. Each one is tiny. Together they add up, and they held across very different populations. The same variants tracked with health, schooling and daily habits. But the team also watched the surroundings push back. Genes load the dice here. They do not roll them. |
| Michigan State University · Nature · September 2026 |
|
|
| A common daily pill drew an eye flag |
| This one is about your eyes. Doctors compared 73,854 men past forty. Half took tadalafil, the daily pill sold as Cialis, for prostate symptoms. Half did not. Over five years the takers had 22% more glaucoma, the slow rise in eye pressure that steals side vision. The authors do not tell anyone to stop. They ask for a pressure check and a follow-up. Sight loss sits on the short list of dementia risks you can act on. That is why it earns a line here. |
| British Journal of Ophthalmology · September 2026 |
|
|
|
|
| |
| Three different doors into the brain today. One is a pill you swallow. One is a spray up the nose. One is a cancer drug taking a second job. None of them is approved. All three sit further along than they did a year ago. |
|
| Blocks the sticky clumps before they harden — as a pill |
| Alzheon calls it valiltramiprosate. You would take it by mouth, twice a day. It goes after the small, loose amyloid clumps rather than the hardened plaque. The trial enrolled 325 people carrying a double dose of the main risk gene. It missed its main goal. But the people caught earliest held their thinking and daily function better, and their scans showed less shrinking. It also skipped the brain swelling and small bleeds that dog the infusion drugs. |
| Phase 3 · results published 2025, new scan data presented 2026 |
|
|
| Teaches the immune system to clear debris — through the nose |
| Protollin is a nasal spray, not a needle. It comes out of Brigham and Women’s Hospital in Boston. The nose sits close to the immune tissue, so the spray uses it as a side door. The first human test was tiny: 16 people with early Alzheimer’s. Afterward their blood immune cells swallowed more debris. Nobody has tested yet whether memory follows. |
| Phase 1 · results published 2025 and 2026 |
|
|
| Switches on the cell’s own waste disposal — a borrowed cancer pill |
| Nilotinib treats leukemia at full strength. At a much smaller dose it seems to prod brain cells into clearing their own rubbish. Charbel Moussa at Georgetown ran the early work. His group has now finished mid-stage trials in Alzheimer’s and in Lewy body dementia. American regulators have cleared the plan for a full trial in early Alzheimer’s. That is a direction worth watching. |
| Phase 2 complete · Phase 3 cleared to begin |
|
|
